Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take on rare solid tumors in first human trial

NCT ID NCT07297667

Recruiting now Disease control Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated Jun 14, 2026 · Updated 24 times

Summary

This early-phase study tests a new treatment called GCAR1, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack cancer cells carrying a specific marker (GPNMB). The study enrolls 30 adults in Canada with advanced alveolar soft part sarcoma, renal cell carcinoma, or triple-negative breast cancer that has not responded to other treatments. The main goals are to find a safe dose and see if the therapy can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Arthur J.E. Child Comprehensive Cancer Centre

    RECRUITING

    Calgary, Alberta, T2N 5G2, Canada

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.

ALVEOLAR SOFT PART SARCOMA RENAL CELL CARCINOMA TRIPLE NEGATIVE BREAST CANCER